Gabapentin
Product Images NDC 50436-4290

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50436-4290). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (50436 0428 1)

This is a description of a medication containing Gabapentin in a 600 mg dose, with 90 tablets per container. The medication has been manufactured by Akem Laboratories and has an NDC number of 6767742805. The package includes a warning to keep the product out of reach of children and to store at controlled room temperature. The package insert should be consulted for dosage information. There are additional details on other products containing Gabapentin with varying doses and quantities per container.*

FDA Label Image

Image Description (50436 4290 1)

This is a description of a medication called Gabapentin, which comes in the form of 90 tablets with a strength of 800 mg per tablet. The NDC number of the drug is 50436-4290-1, and the lot number is X000 P 000X. The manufacturer is not clear, but the NOC number is SDU6-4250-1. There is a warning to keep the medicine out of reach of children and store it at a temperature of 20-25°C (66.77°F) with a lot expiration of 04/7S. The rest of the text is not readable due to errors.*

FDA Label Image

Gabapentin Equation (Gabapentin Equation)

This is a medical formula used to estimate a patient's creatinine clearance (CLCr), which is a measure of kidney function. It involves multiplying the patient's serum creatinine level (in mg/dL) by 72, then dividing by their age and multiplying by a correction factor for female patients (0.85). The result is an estimate of the patient's CLCr in mL/min. The number "140-ight" is likely a scanning error and is not relevant to the formula.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

The text describes a clinical study with a 4-week dose titration period followed by a 4-week fixed dose period. The study reports mean pain score data with a baseline score of 1. The treatment arms include a placebo group and a group treated with 3600mg/day gabapentin.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

This appears to be a table or chart displaying mean pain scores for different treatment periods and doses of gabapentin. The first column indicates the time period, with a baseline measurement and a 4-week fixed dose period. The second column lists the treatment options, including a placebo and two different doses of gabapentin. The remaining columns display the mean pain scores for each treatment option during the specified time periods. Overall, this information may be useful for healthcare professionals or researchers studying the effectiveness of gabapentin for pain management.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

The text includes a figure showing the proportion of responders in patients with a 50% reduction in pain score in controlled PHN studies. The figure includes percentages ranging from 0% to 100%, along with specific percentages for each study (represented by Study |, GBP 3600, PBO, GEBP 1800, and GBP 2400). The figure also includes symbols indicating statistical significance (p<00l, <0.001). No other information is available.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.